Wang Chen, Ma Wenxia, Wei Rong, Zhang Xiaoqin, Shen Ningning, Shang Lifang, E Li, Wang Ying, Gao Lifang, Li Xin, Wang Bin, Zhang Yaping, Du Aiping
Department of Pathology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, P.R. China.
Oncotarget. 2017 Oct 23;8(65):109732-109739. doi: 10.18632/oncotarget.21962. eCollection 2017 Dec 12.
Checkpoint with Forkhead-associated and Ring finger domains () is a G2/M checkpoint and tumor-suppressor gene. Recent publications showed the correlation of promoter methylation with clinicopathological significance of non-small cell lung cancer (NSCLC), however, the results remain inconsistent. The aim of this study is to investigate the Clinicopathological significance of promoter methylation in NSCLC with a meta-analysis. A total of nine studies were included in the meta-analysis that 816 patients were involved. Our data indicated that the frequency of promoter methylation was higher in NSCLC than in normal lung tissue, Odd Ratios (OR) was 9.92 with 95% corresponding confidence interval (CI) 2.17-45.23, = 0.003. Further subgroup analysis revealed that promoter was more frequently methylated in squamous cell carcinoma (SCC) than in adenocarcinoma (ADC), OR was 4.46 with 95% CI 1.65-12.05, = 0.003, suggesting the mechanism of SCC pathogenesis is different from ADC. Notably, promoter methylation was correlated with smoking behavior in NSCLC. In conclusion, could be a biomarker for diagnosis of NSCLC, and a promising drug target for development of gene therapy in SCC. promoter methylation is potentially associated with poor overall survival, additional studies need to be carried out for confirmation in future.
具有叉头相关结构域和环指结构域的检查点（）是一种G2/M期检查点和肿瘤抑制基因。近期的出版物显示了该基因启动子甲基化与非小细胞肺癌（NSCLC）临床病理意义之间的相关性，然而，结果仍不一致。本研究的目的是通过荟萃分析探讨NSCLC中该基因启动子甲基化的临床病理意义。荟萃分析共纳入9项研究，涉及816例患者。我们的数据表明，NSCLC中该基因启动子甲基化的频率高于正常肺组织，优势比（OR）为9.92，95%相应置信区间（CI）为2.17 - 45.23，P = 0.003。进一步的亚组分析显示，该基因启动子在鳞状细胞癌（SCC）中的甲基化频率高于腺癌（ADC），OR为4.46，95% CI为1.65 - 12.05，P = 0.003，提示SCC发病机制与ADC不同。值得注意的是，该基因启动子甲基化与NSCLC中的吸烟行为相关。总之，该基因可能是NSCLC诊断的生物标志物，也是SCC基因治疗开发中有前景的药物靶点。该基因启动子甲基化可能与总体生存率差有关，未来还需要进行更多研究予以证实。
